4.3 Article

The DNMT1 inhibitor GSK-3484862 mediates global demethylation in murine embryonic stem cells

Journal

EPIGENETICS & CHROMATIN
Volume 14, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13072-021-00429-0

Keywords

DNA methylation; DNMT1; GSK-3484862; GSK-3685032; 5-Azacytidine; Decitabine; Demethylation; Whole-genome bisulfite sequencing

Funding

  1. New Frontiers in Research Fund (NFRF) Grant [NFRFE-2018-00883]
  2. Canadian Institutes of Health Research (CIHR) Project [PJT-166169]
  3. Canadian Cancer Society [706002]
  4. McGill University Faculty of Medicine

Ask authors/readers for more resources

In this study, a non-covalent DNMT1 inhibitor GSK-3484862 was found to induce dramatic demethylation in mESCs with minimal non-specific toxicity, whereas 5-azanucleosides showed weaker demethylation effects.
Background DNA methylation plays an important role in regulating gene expression in mammals. The covalent DNMT1 inhibitors 5-azacytidine and decitabine are widely used in research to reduce DNA methylation levels, but they impart severe cytotoxicity which limits their demethylation capability and confounds interpretation of experiments. Recently, a non-covalent inhibitor of DNMT1 called GSK-3484862 was developed by GlaxoSmithKline. We sought to determine whether GSK-3484862 can induce demethylation more effectively than 5-azanucleosides. Murine embryonic stem cells (mESCs) are an ideal cell type in which to conduct such experiments, as they have a high degree of DNA methylation but tolerate dramatic methylation loss. Results We determined the cytotoxicity and optimal concentration of GSK-3484862 by treating wild-type (WT) or Dnmt1/3a/3b triple knockout (TKO) mESC with different concentrations of the compound, which was obtained from two commercial sources. Concentrations of 10 mu M or below were readily tolerated for 14 days of culture. Known DNA methylation targets such as germline genes and GLN-family transposons were upregulated within 2 days of the start of GSK-3484862 treatment. By contrast, 5-azacytidine and decitabine induced weaker upregulation of methylated genes and extensive cell death. Whole-genome bisulfite sequencing showed that treatment with GSK-3484862 induced dramatic DNA methylation loss, with global CpG methylation levels falling from near 70% in WT mESC to less than 18% after 6 days of treatment with GSK-3484862. The treated cells showed a methylation level and pattern similar to that observed in Dnmt1-deficient mESCs. Conclusions GSK-3484862 mediates striking demethylation in mESCs with minimal non-specific toxicity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available